

Medications for Opioid Use Disorder

For Healthcare and Addiction Professionals, Policymakers, Patients, and Families

UPDATED 2020

TREATMENT IMPROVEMENT PROTOCOL

TIP 63



SAMHSA

Substance Abuse and Mental Health
Services Administration



Patient Counseling Tool for XR-NTX

Patient Counseling Tool

VIVITROL® (naltrexone for extended-release injectable suspension)

Risk of sudden opioid withdrawal during initiation and re-initiation of VIVITROL

Using any type of opioid including street drugs, prescription pain medicines, cough, cold or diarrhea medicines that contain opioids, or opioid dependence treatments buprenorphine or methadone, in the 7 to 14 days before starting VIVITROL may cause severe and potentially dangerous sudden opioid withdrawal.

Risk of opioid overdose

Patients may be more sensitive to the effects of lower amounts of opioids:

- After stopping opioids (detoxification)
- If a dose of VIVITROL is missed
- When the next VIVITROL dose is due
- After VIVITROL treatment stops

Patients should tell their family and people close to them about the increased sensitivity to opioids and the risk of overdose even when using lower doses of opioids or amounts that they used before treatment. Using large amounts of opioids, such as prescription pain pills or heroin, to overcome effects of VIVITROL can lead to serious injury, coma, and death.

Risk of severe reactions at the injection site

Remind patients of these **possible** symptoms at the **injection site**:

- Intense pain
- Blisters
- The area feels hard
- Open wound
- Large areas of swelling
- Dark scab
- Lumps

Some of these injection site reactions have required surgery. Tell your patients to contact a healthcare provider if they have any reactions at the injection site.

Risk of liver injury, including liver damage or hepatitis

Remind patients of the **possible symptoms of liver damage or hepatitis**.

- Stomach area pain lasting more than a few days
- Yellowing of the whites of eyes
- Dark urine
- Tiredness

Patients may not feel the therapeutic effects of opioid-containing medicines for pain, cough or cold, or diarrhea while taking VIVITROL.

Patients should carry written information with them at all times to alert healthcare providers that they are taking VIVITROL, so they can be treated properly in an emergency.

A Patient Wallet Card or Medical Alert Bracelet can be ordered from: 1-800-848-4876, Option #1.

PLEASE SEE PRESCRIBING INFORMATION AND MEDICATION GUIDE.



Alkermes® and VIVITROL® are registered trademarks of Alkermes, Inc.
©2013 Alkermes, Inc.
All rights reserved VIV-001317 Printed in U.S.A
www.vivitrol.com

Vivitrol[®]
(naltrexone for extended-release injectable suspension)

Available online (www.vivitrolrems.com/content/pdf/patinfo-counseling-tool.pdf).

Reprinted with permission.⁵³